

Curriculum Vitae

Personal information Ingrid Bourges

Work experience

1. Employer: Federal Agency for Medicines and Health Products
 - Start date: 02/2015
 - End date: current
 - Position: Clinical Assessor (and Coordinator since 05/2024)
 - Activities: Member of the clinical team of the FAMHP (FAGG/AFMPS) in Brussels, working in collaboration with the European Medical Agency, for the evaluation of clinical trials / dossiers in relation with marketing authorizations and variations (vaccines, drugs, biologics, generics and biosimilars). Involved in national, European Centralized, RMP, DCP procedures, scientific/technical advices, Unmet Medical Need Procedures... Expertise in vaccines, oncology, osteoarticular & rheumatic disorders, biosimilars and Advanced Therapy Medicinal products.
 - Country: Belgium
2. Employer: Bone Therapeutics S.A.
 - Start date: 04/2010
 - End date: 01/2015
 - Position: Scientific and Business Administration Senior Manager
 - Activities: Bone Therapeutics is a cell therapy R&D SME developing innovative cell products (ATMP) to regenerate and repair bone and joint tissues (most advanced product in clinical phase III).
 - Country: Belgium
3. Employer: Michael Page Healthcare & Life Sciences Brussels
 - Start date: 02/2010
 - End date: 03/2010
 - Position: Recruiting consultant
 - Activities: Permanent placements realized in pharmaceutical industry.
 - Country: Belgium
4. Employer: Kelly Scientific Resources Brussels
 - Start date: 07/2008
 - End date: 01/2010
 - Position: Recruiting consultant
 - Activities: Placements (temporary and permanent) realized in a broad field of industries: pharmaceutical, chemical, biotechnology, clinical, nanotechnology, agronomy,...
 - Country: Belgium
5. Employer: Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA
 - Start date: 04/2006
 - End date: 06/2008
 - Position: Post_Doctoral fellow
 - Activities: Study of the role of SOD1 in the amyotrophic lateral sclerosis, a neurodegenerative disease, and development of gene therapy for this disease
 - Country: United States
6. Employer: The Wolfson Institute for Biomedical Research, University College London, London
 - Start date: 09/2003
 - End date: 03/2006
 - Position: Post_Doctoral fellow
 - Activities: Analysis of the genomic responses to the inhibition of the mitochondrial bc1 complex and cytochrome oxidase (studied in yeast)
 - Country: United Kingdom

Education and training

1. Subject: Ph.D. Characterization of the assembly pathway of human mitochondrial complex I
 - Start date: 09/1999
 - End date: 04/2003
 - Qualification: Ph.D. in Molecular and Cellular Biology
 - Organisation: Université Joseph Fourier / Grenoble
 - Country: France
2. Subject: Master in Molecular and Cellular Biology
 - Start date: 09/1997
 - End date: 06/1999
 - Qualification: Master in Molecular and Cellular Biology
 - Organisation: Université Joseph Fourier / Grenoble
 - Country: France

Additional information

Publications

Kurki P, Barry S, Bourges I, Tsantili P, Wolff_Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs. 2021 Oct 1. doi: 10.1007/s40265-021-01601-2.

Bourges, I., Mucchielli, M.H., Herbert, C.J., Guiard, B., Dujardin, G., Meunier, B. (2009) Multiple defects in the

respiratory chain lead to the repression of genes encoding components of the respiratory chain and TCA cycle enzymes. *J Mol Biol.* 17;387(5):1081_91.

Horan, S., Bourges, I., and Meunier, B. (2006) Transcriptional response to nitrosative stress in *Saccharomyces cerevisiae*. *Yeast*, 23, 519_535.

Horan, S., Bourges, I., Taanman J.W., and Meunier, B. (2005) Analysis of COX2 mutants reveals cytochrome oxidase subassemblies in yeast. *Biochem. J.*, 390(3), 703_708.

Bourges, I., Horan, S., and Meunier, B. (2005) Effect of inhibition of the bc1 complex on gene expression profile in yeast. *J. Biol. Chem.* 280(33), 29743_29749.

Fisher, N., Bourges, I., Hill, P., Brasseur, G., and Meunier, B. (2004) Disruption of the interaction between the Rieske iron_sulfur protein and cytochrome b in the yeast bc1 complex owing to a human disease-associated mutation within cytochrome b. *Eur. J. Biochem.* 271(7), 1292_1298.

Fisher, N., Castleden, C.K., Bourges, I., Brasseur G., Dujardin, G., and Meunier, B. (2004) Human disease-related mutations in cytochrome b studied in yeast. *J. Biol. Chem.* 279(13), 12951_12958.

Bourges, I., Mousson de Camaret, B., Ramus, C., Beugnot, R., Remacle, C., Cardol, P., Hofhaus, G., and Issartel, J. P. (2004) Structural organization of mitochondrial human complex I: role of ND4 and ND5 mitochondria-encoded subunits and interaction with the prohibitin. *Biochem. J.* 383, 491_499

Procaccio, V., Lescuyer, P., Bourges, I., Beugnot, R., Duborjal, H., Depetris, D., Mousson, B., Montfort, M.F., Smeets, H., De Co, R., and Issartel, J. P. (2000) Human NDUFS3 gene coding for the 30 kDa subunit of mitochondrial complex I: genomic organization and expression. *Mamm. Genome* 11(9), 808_810.

Projects

Previous involvements in cellular therapy projects:

Quality research projects: Development, set up and validation of: GMP industrial process for production, storage and distribution with its associated Quality Assurance system; Alternative analytical methods (in process quality control and batch release)

Non-clinical research projects : Development of autologous and allogeneic differentiated cellular products for bone regeneration, and in vitro & in vivo preclinical tests (characterisation, stability, efficacy, toxicity...); Development of tailored 3D cellular_matrix product (tissue engineering); Development of a technology platform for full tissue regeneration of a range of critical sized bone defects (BIOINSPIRE – EU FP7)

Clinical research projects : Phase 2b/3 study on autologous osteoblastic cells implantation in hypotrophic non_union fractures; Phase 3 study on autologous osteoblastic cells implantation to early stage osteonecrosis of the femoral head; Phase 1/2a study on allogeneic osteoblastic cells implantation in delayed_union fractures; Phase 2a study on allogeneic osteoblastic cells implantation in lumbar spinal fusion

Memberships

Member and scientific secretary of the HMA working group of Biosimilars (BSWG)

Member of thematic Expert Panel FWO / TBM in Belgium Invited member of international expert panel to determine Flemish funding of "Applied Biomedical research with a primary Societal goal" ("Toegepast Biomedisch Onderzoek met een Primair Maatschappelijke Finaliteit _ TBM")

Other Relevant Information